Navigation
Company
The Company
Leadership
Board of Directors
Our Science
mTOR Pathway
TSC1
&
TSC2
nab
Technology Platform
Publications and Abstracts
Our Medicine
Our Medicine
Advanced Malignant PEComa
Expanded Access
Pipeline
Patients
Overview
Patient Advocacy
Clinical Trials
Investors & News
IR Overview
Stock
Stock Quote & Chart
Analyst Coverage
Press Releases
Event Calendar
Presentations
Corporate Presentations
Scientific Presentations
Financial
SEC Filings
Financial Reports
Quarterly Results
Forms
Governance
Governance Highlights
Committee Composition
IR Resources
Investor FAQ
Information Request
Email Alerts
IR Contacts
Contact Us
General Contact
For Healthcare Professionals
Careers
nab
-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors
Home
nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors
Next Post
Previous Post
nab
-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors
October 12, 2021
/
Publications
Like
this post!
Share
the Post
About
the Author
Related
Posts
Analysis of inactivating
TSC1
and
TSC2
alterations in a real-world patient population with advanced gynecological cancers in the Foundation Medicine genomic database
Read More
Dave Lennon
UPDATE – Aadi Bioscience Presents Two Abstracts on FYARRO (
nab
-Sirolimus) at the Annual Meeting of the Connective Tissue Oncology Society (CTOS)
Aadi Bioscience to Participate in Upcoming Investor Conferences
Mutational analysis and safety/efficacy in a phase 2 multi-center investigation of ABI-009 (
nab
-rapamycin) in patients with advanced malignant perivascular epithelioid cell tumors (PEComa)
Read More
Stephen Rodin, JD
Aadi Bioscience to Participate at the Jefferies “Biotech on the Bay” Summit
nab
-Sirolimus Plus Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer: A Phase 2, Open-Label, Single-Arm, Prospective, Multicenter Study
Comments
Comments are closed.
Next Post
Previous Post
Comments
Comments are closed.